| 1 |
35131254 | Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study. | 2022 Feb 5 |
1 |
| 2 |
35218354 | Ruxolitinib Inhibits IFNγ-stimulated Sjögren's Salivary Gland MSC HLA-DR Expression and Chemokine-Dependent T-cell Migration. | 2022 Feb 26 |
5 |
| 3 |
35266648 | Interferon-gamma induces melanogenesis via post-translational regulation of tyrosinase. | 2022 May |
1 |
| 4 |
32201152 | Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review. | 2021 Sep |
1 |
| 5 |
33965175 | Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. | 2021 May |
10 |
| 6 |
34171557 | Regulation of CD47 expression by interferon-gamma in cancer cells. | 2021 Sep |
2 |
| 7 |
34232994 | JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition. | 2021 Sep 23 |
2 |
| 8 |
34868078 | Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. | 2021 |
1 |
| 9 |
32492985 | The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway. | 2020 Jul |
4 |
| 10 |
32536506 | Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. | 2020 Aug |
2 |
| 11 |
32698510 | The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells. | 2020 Jul 20 |
3 |
| 12 |
33087723 | Early-onset autoimmunity associated with SOCS1 haploinsufficiency. | 2020 Oct 21 |
1 |
| 13 |
30846331 | Interferon-γ upregulates Δ42PD1 expression on human monocytes via the PI3K/AKT pathway. | 2019 May |
1 |
| 14 |
31354696 | STAT1 Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal Dephosphorylation. | 2019 |
1 |
| 15 |
31484895 | [Ruxolitinib for treatment of GvHD in patients with myelofibrosis]. | 2019 |
1 |
| 16 |
27923824 | Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade. | 2017 Jan |
1 |
| 17 |
26085921 | Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery. | 2015 |
1 |
| 18 |
24406841 | Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. | 2014 Jul |
1 |
| 19 |
24711661 | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. | 2014 Jun 12 |
1 |
| 20 |
24764577 | JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. | 2014 Apr |
1 |